Breye Therapeutics Series A: €67.5M

Oct 1, 2026Public sources — Collected from public sources, not yet cross-checked.

Breye Therapeutics raised €67.5 million (about $75.77 million) in a series a round led by Mission BioCapital and Novo Holdings, announced Oct. 1.

Facts

Company: Breye Therapeutics
Amount: €67.5 million (about $75.77 million)
Currency: EUR
Stage: Series A
Announced: Oct 1, 2026
Instrument: Equity
FX rate: 1 EUR = 1.1225 USD on Oct 1, 2026

Investors

Led by: Mission BioCapital Novo Holdings
Participants: Sound Bioventures Ljungström family office Innovestor Life Science EIFO Catalyze Capital Modi Ventures Pappas Capital

Use of funds

To advance the lead asset danegaptide into a randomised Phase 2 clinical trial and support the company's broader pipeline of oral small molecules.

As stated by the company.

Sources

1.Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases — EU-Startups, Oct 2, 2026

Public sources — Collected from public sources, not yet cross-checked.Last verified Oct 15, 2026